Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance

[1]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[2]  Joachim Herz,et al.  Apolipoprotein E receptors in the nervous system , 2009, Current opinion in lipidology.

[3]  D. Russell,et al.  Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan , 2009, Proceedings of the National Academy of Sciences.

[4]  H. Mount,et al.  Brainstem Concentrations of Cholesterol are not Influenced by Genetic Ablation of the Low-Density Lipoprotein Receptor , 2009, Neurochemical Research.

[5]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[6]  P. S. St George-Hyslop,et al.  Loss of γ-Secretase Function Impairs Endocytosis of Lipoprotein Particles and Membrane Cholesterol Homeostasis , 2008, The Journal of Neuroscience.

[7]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[8]  H. Soininen,et al.  Genetic study evaluating LDLR polymorphisms and Alzheimer's disease , 2008, Neurobiology of Aging.

[9]  D. Holtzman,et al.  Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease , 2008, Nature.

[10]  D. Holtzman,et al.  Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. , 2008, The Journal of clinical investigation.

[11]  D. Bennett,et al.  Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease. , 2007, Human molecular genetics.

[12]  Frank Z. Stanczyk,et al.  Progesterone and Estrogen Regulate Alzheimer-Like Neuropathology in Female 3xTg-AD Mice , 2007, The Journal of Neuroscience.

[13]  R. Vassar,et al.  Molecular Neurodegeneration BioMed Central Review The Alzheimer's disease β-secretase enzyme, BACE1 , 2007 .

[14]  L. Muglia,et al.  Amyloid Precursor Protein Regulates Brain Apolipoprotein E and Cholesterol Metabolism through Lipoprotein Receptor LRP1 , 2007, Neuron.

[15]  J. Buxbaum,et al.  Elevated plasma cholesterol does not affect brain Aβ in mice lacking the low‐density lipoprotein receptor , 2007, Journal of neurochemistry.

[16]  D. Holtzman,et al.  Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  A. Soutar,et al.  Mechanisms of Disease: genetic causes of familial hypercholesterolemia , 2007, Nature Clinical Practice Cardiovascular Medicine.

[18]  D. Blacker,et al.  The LDLR locus in alzheimer's disease: A family-based study and meta-analysis of case-control data , 2007, Neurobiology of Aging.

[19]  D. Dickson,et al.  Aβ40 Inhibits Amyloid Deposition In Vivo , 2007, The Journal of Neuroscience.

[20]  D. Holtzman,et al.  Apolipoprotein E and Low Density Lipoprotein Receptor-related Protein Facilitate Intraneuronal Aβ42 Accumulation in Amyloid Model Mice* , 2006, Journal of Biological Chemistry.

[21]  K. Fukuchi,et al.  Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice , 2006, Neurobiology of Aging.

[22]  John Hardy,et al.  A Hundred Years of Alzheimer's Disease Research , 2006, Neuron.

[23]  Tony Wyss-Coray,et al.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.

[24]  G. Bu,et al.  Modulation of β-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family , 2006, Molecular Neurodegeneration.

[25]  O. Combarros,et al.  No association between low density lipoprotein receptor genetic variants and Alzheimer's disease risk , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[26]  D. Holtzman,et al.  Deletion of Abca1 Increases Aβ Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease* , 2005, Journal of Biological Chemistry.

[27]  M. Staufenbiel,et al.  Lack of ABCA1 Considerably Decreases Brain ApoE Level and Increases Amyloid Deposition in APP23 Mice* , 2005, Journal of Biological Chemistry.

[28]  M. Hayden,et al.  The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease* , 2005, Journal of Biological Chemistry.

[29]  Rena Li,et al.  Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Holtzman,et al.  The Low Density Lipoprotein Receptor Regulates the Level of Central Nervous System Human and Murine Apolipoprotein E but Does Not Modify Amyloid Plaque Pathology in PDAPP Mice* , 2005, Journal of Biological Chemistry.

[31]  E. Corder,et al.  Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer’s disease , 2005, Journal of Medical Genetics.

[32]  David A. Bennett,et al.  Genetic association of low density lipoprotein receptor and Alzheimer's disease , 2005, Neurobiology of Aging.

[33]  D. Holtzman,et al.  Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Bruce J Aronow,et al.  ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo , 2004, Neuron.

[35]  Joanna L. Jankowsky,et al.  Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .

[36]  J. Dietschy,et al.  Ontogenesis and regulation of cholesterol metabolism in the central nervous system of the mouse. , 2003, Brain research. Developmental brain research.

[37]  Heikki Tanila,et al.  Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice , 2003, Neurobiology of Disease.

[38]  D. Holtzman,et al.  In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.

[39]  M. Staufenbiel,et al.  Extracellular amyloid formation and associated pathology in neural grafts , 2003, Nature Neuroscience.

[40]  Sascha Weggen,et al.  The cytoplasmic domain of the LDL receptor‐related protein regulates multiple steps in APP processing , 2002, The EMBO journal.

[41]  Bruce J Aronow,et al.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Sangram S. Sisodia,et al.  γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in? , 2002, Nature Reviews Neuroscience.

[43]  J. Thome,et al.  Potential genetic markers of sporadic Alzheimer's dementia , 2001, Psychiatric genetics.

[44]  F. Bian,et al.  Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. , 2001, The American journal of pathology.

[45]  C. Haass,et al.  Intramembrane proteolysis by presenilins , 2000, Nature Reviews Molecular Cell Biology.

[46]  A. Fagan,et al.  Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model , 2000, Annals of neurology.

[47]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[48]  B. Hyman,et al.  Modulation of β-Amyloid Precursor Protein Processing by the Low Density Lipoprotein Receptor-related Protein (LRP) , 2000, The Journal of Biological Chemistry.

[49]  S. Paul,et al.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  A Hofman,et al.  Gender differences in the incidence of AD and vascular dementia , 1999, Neurology.

[51]  D L Price,et al.  A vector for expressing foreign genes in the brains and hearts of transgenic mice. , 1996, Genetic analysis : biomolecular engineering.

[52]  J. B. Justice,et al.  In vivo calibration of microdialysis probes for exogenous compounds. , 1992, Analytical chemistry.

[53]  R. Hammer,et al.  Diet-induced hypercholesterolemia in mice: prevention by overexpression of LDL receptors. , 1990, Science.

[54]  I. Filipović.  Effect of inhibiting N-glycosylation on the stability and binding activity of the low density lipoprotein receptor. , 1989, The Journal of biological chemistry.

[55]  E. Krul,et al.  Heterogeneity of apolipoprotein E epitope expression on human lipoproteins: importance for apolipoprotein E function. , 1988, Journal of lipid research.

[56]  R. Hammer,et al.  Overexpression of low density lipoprotein (LDL) receptor eliminates LDL from plasma in transgenic mice. , 1988, Science.

[57]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[58]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[59]  D. Dickson,et al.  Abeta40 inhibits amyloid deposition in vivo. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[60]  M. Hofker,et al.  Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice , 2005, Clinical chemistry and laboratory medicine.

[61]  D. Borchelt,et al.  Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. , 2004, Human molecular genetics.

[62]  P. S. St George-Hyslop,et al.  gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? , 2002, Nature reviews. Neuroscience.

[63]  H. Bock,et al.  Lipoprotein receptors in the nervous system. , 2002, Annual review of biochemistry.

[64]  R. Mahley,et al.  Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. , 1999, Journal of lipid research.

[65]  S. Paul,et al.  Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. , 1997, Nature genetics.